Skip to main content

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA.

The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms.

In this guidance, the FDA provides recommendations for the conduct of studies involving multiple versions of cellular or gene therapy products. This includes guidance on how to structure and manage the INDs, submit new data, and report adverse events.



Key points in the guidance include:

IND Organization: Sponsors should submit separate INDs for each product version in the study. One IND is designated as the "Primary," including clinical and Chemistry, Manufacturing, and Controls (CMC) and Pharmacology/Toxicology (P/T) information for one product. Others are "Secondary" INDs, including CMC and P/T data for other products. Cross-referencing is encouraged to minimize redundant information submission.


Adding Study Arms: When adding arms to the study, especially those involving new product versions, sponsors should submit new Secondary INDs with relevant information and amend the Primary IND to incorporate these changes. Cross-references ensure consistency.


Submitting Changes: For changes to the clinical protocol that don't introduce new arms and for new clinical information, submit these updates to the Primary IND only. New CMC or P/T information specific to one product should be submitted to the corresponding IND(s).


Clinical Holds: If a clinical hold is issued for one arm or for the entire study, responses should be submitted to the relevant IND(s). Detailed responses don't need to be duplicated across multiple INDs, promoting efficiency.


Reporting: Safety reports must be submitted to all relevant INDs. Annual reports can be integrated and submitted to the Primary IND, with cross-references in Secondary INDs.


Study Completion or Changes: If a product is discontinued from the study, the Primary IND should not be withdrawn but updated. If the Primary IND is withdrawn, a new Primary IND should be designated. When transitioning to later-phase studies, submit protocols and updates accordingly.


Alternative Approaches: The guidance acknowledges alternative approaches for organizing INDs but advises sponsors to engage with the FDA for regulatory guidance and adhere to regulatory requirements.

Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial 

https://www.fda.gov/media/152536/download

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quantification of si
Read more

Standard Template For Clinical Study Report (CSR)-Gene Therapy

 A Standard Format for a Clinical Study Report (CSR) typically includes the following sections and components: Title Page: Title of the Clinical Study Report Study Title Protocol Number Version Date Sponsor's Name and Logo Date of Report Compilation Table of Contents: A list of all sections, subsections, and appendices with page numbers for easy navigation. List of Abbreviations and Glossary: A compilation of all abbreviations used throughout the report, along with their definitions. Executive Summary: A concise overview of the study, including objectives, methods, key findings, and conclusions. Introduction: Background and rationale for the study. Study objectives and hypotheses. Study Design and Methods: Detailed information about the study design, including: Inclusion and exclusion criteria. Study population and recruitment. Randomization and blinding procedures. Data collection methods and tools. Statistical analysis plan. Ethical Considerations: Information on ethical approval
Read more